Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Targanta Therapeutics

October 10, 2011

Angiomax outlook improves but Medicines Company needs more options

March 24, 2010

EP Vantage Interview - Rib-X gears up for action in antibiotic space

Vantage logo
June 22, 2009

Forest's antibiotic looks value for money as filing approaches

Vantage logo
January 16, 2009

Predators gaining power and increasingly able to hedge their bets

Vantage logo
January 14, 2009

Medicines Company scoops up drowning Targanta

Vantage logo
December 10, 2008

Targanta takes on a challenge and vows to continue with oritavancin

Vantage logo
November 28, 2008

Companies desperate for a partner

Vantage logo
November 27, 2008

One-product companies currently on a knife edge

Vantage logo
November 27, 2008

Therapeutic focus - recent antibiotic setbacks disappointing for already slow field

Vantage logo
November 20, 2008

Event - Targanta and Theravance face short wait for final FDA decisions

Vantage logo
November 18, 2008

Targanta and Theravance rise on hopes of positive antibiotic review

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2020 Evaluate Ltd.